Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

View Full Paper
Ask AI
Bookmark
Share

Authors

CJChristopher E. JensenNLNicole LamannaPBPaul Barr

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds no tumor lysis syndrome during venetoclax ramp-up in chronic lymphocytic leukemia patients, suggesting manageable outpatient treatment.

Key Points

  • No tumor lysis syndrome reported during venetoclax ramp-up in patients with chronic lymphocytic leukemia.
  • In 72 patients, 37.5% received prophylactic IV hydration prior to dose escalation, based on physician assessment.
  • Observational analysis across 4 US sites provided insights into venetoclax initiation and monitoring protocols.
  • Results support outpatient initiation of venetoclax, highlighting potential for simplified monitoring requirements.

Cite This Study

Jensen et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86dhttps://doi.org/10.1182/blood-2025-3885
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia2025
  2. 2Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population2025
  3. 3Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia2025
  4. 4Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL2025
  5. 5Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group2025 · 3 citations